A systematic review of Hepatitis B virus (HBV) prevalence and genotypes in Kenya: Data to inform clinical care and health policy

Louise O Downs[1,2], Cori Campbell[1], Paul Yonga[3], M. Azim Ansari[1], Philippa C Matthews[1,4,5,6¶*] and Anthony O. Etyang[¶7]

[1] Nuffield Department of Medicine, Medawar Building for Pathogen Research, University of Oxford, South Parks Road, Oxford, UK

[2] Department of Infectious Diseases and Microbiology, John Radcliffe Hospital, Headley Way, Oxford, UK

[3] CA Medlynks Clinic and Laboratory, Nairobi, and Fountain Projects and Research Office, Fountain Health Care Hospital, Eldoret, Kenya

[4] The Francis Crick Institute, 1 Midland Way, London, UK

[5] Division of Infection and Immunity, University College London, London, London, UK

[6] Department of Infectious Diseases, University College London Hospital, London, London, UK

[7] KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

Key words: hepatitis B virus, HBV, epidemiology, serology, serosurveillance, prevalence, Kenya, Africa, genotype, drug resistance, treatment

* Corresponding author - Email: philippa.matthews@crick.ac.uk

¶These two authors contributed equally to this work

23

Abstract

More than 20% of the global disease burden from chronic hepatitis B infection (CHB) is in Africa, however there is minimal high quality seroprevalence data from individual countries and little viral sequencing data available to represent the continent. We undertook a systematic review of the prevalence and genetic data available for hepatitis B virus (HBV) in Kenya using the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) 2020 checklist. We identified 23 studies reporting HBV prevalence and 25 studies that included HBV genetic data published in English between January 2000 and December 2021. We assessed study quality using the Joanna Briggs Institute critical appraisal checklist. Due to study heterogeneity, we divided the studies to represent low, moderate, high and very high-risk for HBV infection. We calculated pooled HBV prevalence within each group and evaluated available sequencing data. We also assessed whether reported HBV biomarkers could be applied to determine treatment eligibility. Eight studies were identified in the low-risk group, seven in the moderate risk group, five in the high-risk group and three in the very high-risk group for HBV infection. Pooled HBV prevalence was 3.31% (95% CI 2.62-4.01%), 5.58% (95% CI 3.46-7.7%), 6.17% (95% CI 4.4-9.94) and 31.39% (95% CI 9.5-53.09) respectively. Study quality was overall low, representing a small geographical location or a limited population subset. Only three studies detailed sample size calculation and 17/23 studies were cross sectional. Eight studies included genetic information on HBV, representing 247 individuals. Six studies sequenced one or two genes; two undertook whole genome sequencing, representing 22 participants. 92% people were infected with genotype A. Other genotypes included genotype D (6%), D/E recombinants (1%) or mixed populations (1%). Drug resistance mutations were reported by two studies. Seven studies presented

47 additional biomarkers alongside HBsAg, however none provided sufficient information to
48 deduce treatment eligibility.
49

50 Introduction

51 Chronic hepatitis B (CHB) infection accounts for an estimated 90,000 deaths annually across
52 West, East and Southern Africa, where most countries are of medium to high prevalence for
53 CHB (prevalence ≥4%), accounting for around 20% of the worldwide burden of disease (1).
54 The World Health Organisation's (WHO) point prevalence estimate of CHB for Africa is 6.1%
55 with some uncertainty (4.6-8.5%), but this varies substantially between settings, and high-
56 quality data for individual countries are scarce (1). CHB meets many of the WHO criteria for
57 a neglected tropical disease, including disproportionately affecting populations living in
58 poverty, being associated with significant stigma and discrimination, and poor investment in
59 clinical infrastructure and research (2). Fewer than 10% of people have access to testing and
60 treatment leading to delayed diagnosis, with associated risks of advanced liver disease and
61 hepatocellular carcinoma (HCC) (1).
62
63 The Global Health Sector Strategy (GHSS) for viral hepatitis aims to eliminate HBV as a public
64 health threat by 2030 by reducing the incidence of new chronic infections by 90% and
65 reducing mortality by 65% from the 2015 baseline to achieve the 2030 WHO Sustainable
66 Development Goals (3). These are ambitious targets, and current estimates indicate they
67 will not be attained until beyond 2050 (4). Detailed seroprevalence data are needed to
68 target testing, treatment, and prevention interventions to the highest risk groups, to
69 allocate resources, and to inform policy.

70 In Kenya, information regarding HBV prevalence is lacking. Most studies focus on specific
71 groups such as blood donors and those living with HIV, which may not be representative of
72 the general population (5–7). Other studies have stringent inclusion criteria, meaning
73 important demographic subgroups remain uncharacterised (8). HBV testing is not done
74 routinely in Kenya, even in antenatal populations. Triple HBV vaccine from the age of 6
75 weeks onwards is recommended by the Kenyan Ministry of Health as a component of the
76 WHO Expanded Programme for Immunization (EPI). It does not however currently
77 recommend the monovalent HBV vaccine at birth, due to a belief that HBV transmission in
78 early life in Kenya is horizontal rather than vertical, in which case birth dose vaccine would
79 offer no significant advantage over vaccination begun at 6 weeks (9). However, more data
80 are needed to underpin evidence-based policy in this domain.
81
82 HBV is divided into 9 genotypes (A-I) with a 10th putative genotype J (10,11); these tend to
83 have distinct geographical locations and have been linked to different outcomes. Genotype
84 A predominates in many African countries and has been associated with horizontal
85 transmission, chronicity, early HBeAg seroconversion (12), cirrhosis and HCC development
86 (13). Genotype also affects response to treatment (including drug resistance), and thus may
87 influence clinical recommendations (12–14), though is not yet widely undertaken in clinical
88 practice in most settings. Most studies of the impact of HBV genotype have been in Asia and
89 Europe. There is a paucity of data on circulating genotypes and subgenotypes in Africa,
90 including Kenya. Whole genome sequencing (WGS) of HBV in Kenya could provide
91 information on transmission networks, disease and treatment outcomes, drug resistance
92 and vaccine escape.
93

94 Guidelines for assessment and treatment of those with CHB typically involve complex
95 algorithms based on biomarkers such as quantitative HBV DNA, and liver stiffness scores
96 based on elastography (14) (Table 1). Regional African guidelines have been published (e.g.
97 by the South African Department of Health (15) and the Gastroenterology Society of Kenya
98 (16)). However, these still require a battery of tests on initial assessment and follow up,
99 which are not universally practical or accessible in many low- and middle-income country
100 (LMIC) settings. Thus, a refined assessment of population characteristics and needs is
101 required to help improve algorithms to better match the circumstances of the local
102 population and to support development of healthcare services.

103

104 **Table 1: Recommendations by various international and national guidelines on assessment of a**
105 **person with chronic hepatitis B infection.**

Summary of recommendations at diagnosis of CHB	**EASL HBV Guidelines** (20)	**Kenyan HBV Guidelines** (18)	**NICE HBV Guidelines (UK)** (17)	**South African HBV Guidelines** (19)
HBV serological markers				
FBC				
LFTs		+ aFP	+ aFP	
PTT				
Albumin				
Liver USS/ fibroscan				
Liver Biopsy				
Successive tests prior to treatment				

106 Red indicates not recommended for treatment decisions, orange indicates recommended if possible, green
107 indicates essential for treatment decision. HBV serological markers – HBsAg (Hepatitis B surface antigen),
108 HBeAg (Hepatitis B e-antigen), HBV DNA (quantitative viral load); FBC – Full blood count; LFTs – Liver function
109 tests; aFP = Alpha-fetoprotein; PTT – Prothrombin time; USS – Ultrasound scan; EASL – European Association
110 for the Study of the Liver; NICE – National Institute for Health and Care Excellence (UK).

111

112 We here assimilate data to describe the serological, clinical and molecular characteristics of
113 HBV infection in Kenya to underpin an evidence-base for local strategies for intervention,
114 and highlight knowledge gaps to inform research. High resolution local data will be essential
115 for development of local clinical care pathways and public health policy, to underpin
116 progress towards the 2030 elimination targets.
117

118 # Methods

119 We set out to review literature on prevalence and genetic characteristics of HBV infection in
120 Kenya, using the Preferred Reporting Items for Systematic Review and Meta-analysis
121 (PRISMA) 2020 statement checklist (S1 Fig). We searched the online databases PubMed,
122 Embase, African Journals Online (AJOL) and Scopus on 6th December 2021 using the terms in
123 table 2. We included studies published in English, from 2000 to December 2021 (from 2003
124 for AJOL) that investigated prevalence, genotype and sequencing of HBV infection in Kenya.
125 We only included data for adults from studies for which the full text was available. There
126 was no minimum number of participants for studies included. We initially screened using a
127 thorough review of the title and abstract, and subsequently reviewed the full manuscripts of
128 eligible articles. Articles that did not meet the inclusion criteria were excluded. Any
129 uncertainty regarding the inclusion of papers was discussed with another reviewer and a
130 consensus obtained.
131

132

133 **Table 2: Search terms for online databases used during a systematic review on HBV prevalence**

134 **and genetic information in Kenya.**

Database searched	Search terms
PubMed	(("Hepatitis B"[Mesh]) OR ("hepatitis b"[Title/Abstract] OR HBV[Title/Abstract] OR "hepatitis type b"[Title/Abstract] OR "type b hepatitis"[Title/Abstract] OR "hep b"[Title/Abstract])) AND (("Kenya"[Mesh]) OR (kenya*[Title/Abstract] OR nairobi*[Title/Abstract] OR mombasa*[Title/Abstract]))
Embase	1 exp hepatitis B/ (109266) 2 ("hepatitis b" or HBV or "hepatitis type b" or "type b hepatitis" or "hep b").ti,ab. (135330) 3 1 or 2 (161216) 4 Kenya/ (22999) 5 (Kenya* or nairobi* or mombasa*).ti,ab. (26384) 6 4 or 5 (29072) 7 3 and 6 (227) 8 limit 7 to yr="2000 -Current" (173)
AJOL	(("Hepatitis B" OR ("hepatitis b" OR HBV OR "hepatitis type b" OR "type b hepatitis" OR "hep b" AND (("Kenya") OR (Kenya* OR nairobi* OR mombasa*))
Scopus	(("Hepatitis B" OR ("hepatitis b" OR HBV OR "hepatitis type b" OR "type b hepatitis" OR "hep b" AND (("Kenya") OR (Kenya* OR nairobi* OR mombasa*))

135 Terms used to search online databases for a systematic review reporting prevalence and genetic data for HBV

136 in Kenya. We also modified search terms to include the 5 largest cities in Kenya (Nairobi, Mombasa, Eldoret,

137 Nakuru and Kisumu with no change to the results).

138

139

140 From each study, we extracted:

141 - Total number of individuals tested for HBV.

142 - Number of individuals found to be infected with HBV (either HBsAg positive or HBV

143 DNA positive)

144 - Study location (city or geographical region)

145 - Participant selection criteria

146 - Laboratory methods for confirmation of HBV infection

147 - Any other measurements taken relating to HBV assessment and liver health

148 - Whether any viral sequencing was undertaken, methods used and results (including

149 genotype, presence of vaccine escape and drug resistance mutations).

150

151 Early in the review, it became obvious the studies would be very heterogenous. On these

152 grounds, we divided them into four groups to represent different risk profiles. The low-risk

153 group included studies most likely to represent the general population (antenatal women,

154 healthcare workers, blood donors and the national survey), the moderate risk group

155 consisted of studies containing populations living with HIV, the high-risk group included

156 intravenous drug users, men who have sex with men (MSM) and sex workers, and the very

157 high-risk group was those presenting to hospital with hepatitis or jaundice.

158

159 Quality assessment of studies

160 A thorough assessment of the study quality was done using the PRISMA guidelines (20) and

161 Joanna Briggs Institute critical appraisal checklist for prevalence studies (S2 Fig) (21). Any

dispute surrounding study quality was discussed with another reviewer and a consensus reached.

Current available Kenyan full-length sequences

We downloaded all full genome HBV sequences from Kenya in GenBank on 1-December-2021 to assimilate a reference set of all whole genome sequences representing Kenya. Sequences were aligned with available HBV reference sequences for each genotype (11) using MAFFT (22). A maximum likelihood phylogenetic tree with bootstrap replicates of 1000 was created using NGPhylogeny.fr (23)

Statistical Analysis

Pooled prevalence estimates for CHB infection (i.e. HBsAg seroprevalence) were generated via meta-analysis using inverse-variance weighting of standard errors. Meta-analysis was conducted in R (version 4.1.1) using the 'meta' package (version 5.2-1). Standard errors for prevalence were calculated using the formula $\sqrt{p(1-p)/n}$, with the total sample size represented by n and the proportion of the sample seropositive for HBV represented by p. Meta-analysis was stratified by cohort risk group. The I^2 statistic was used to quantify the heterogeneity between studies within each risk group, calculated using $I^2 = 100\% \times (Q-df)/Q$ where Q – Cochran's coefficient and df = degrees of freedom. Pooled estimates from fixed and random effects models are presented for each risk group. Where heterogeneity was statistically significant, results from random effects models were discussed. Study site locations were identified using latitudinal and longitudinal data from Googlemaps based on

where the study was conducted. The map plot was created in R (version 4.1.1) using 'rworldmap' (verion 1.3-6) 'ggmap' (version 3) and 'ggplot2' (version 3.3.5) packages.

Occult HBV infection

Occult HBV infection (OBI) is defined as detectable HBV DNA in the absence of HBsAg. Where studies reported both HBsAg positivity rates and OBI rates in those who were HBsAg negative, only prevalence data based on HBsAg positivity was included in the meta-analysis, in order to ensure datasets were comparable between studies.

Review of treatment guidelines

We reviewed clinical and laboratory data necessary to make HBV treatment decisions based on the National Institute for Health and Care Excellence (NICE) (17), European Association for the Study of the Liver (EASL) (24), National South African (19) and Kenyan guidelines (18) on the management of CHB (Table 1). For each study reporting factors involved in treatment decisions, we reviewed the information available and compared it to the treatment guidelines. We then reviewed the proportion of study participants who would meet treatment criteria by each of these guidelines.

Results

(i) Identification of Studies

We identified 272 published studies, of which 23 studies met the inclusion criteria, representing a total of 11,467 people (Figure 1 and Table 3). Three of these studies also

206 screened individuals for occult HBV infection (OBI) in a total of 666 people using HBV DNA
207 polymerase chain reaction (PCR) in addition to testing for HBsAg seroprevalence. Two
208 studies screened initially with HBsAg, then with HBV DNA PCR on those who were HBsAg
209 negative (25,26). A further study included two different populations: a) those attending a
210 clinic for sex workers, whom they screened initially for HBsAg, then HBV PCR in those who
211 were HBsAg negative and b) known HBsAg negative, jaundiced participants whom they
212 screened with HBV DNA PCR to detect OBI (27).
213
214 **Figure 1: Flow chart for eligibility of studies included in a systematic review reporting prevalence**
215 **and genetic data for HBV in Kenya between 2000 – 2021** (AJOL: African Journal Online).
216 **Table 3: Characteristics of the studies included in the systematic review reporting prevalence and**
217 **genetic data for HBV in Kenya.**

First Author	Year	N	Location	HBV +ve (%)	Data collection method	Study design	Sampling type	Population recruitment location	Population Investigated	Detection Method
Very high-risk populations (total 3 studies representing 492 individuals)										
Atina JO (28)	2004	60	Nairobi	30	Prospective	Cross sectional	Non-random	Hospital	Hepatitis	RPHA
Muchiri I (29)	2013	100	Nairobi	13	Prospective	Cross sectional	Non-random	Hospital	Hepatitis	RPHA
Ochwoto M (30)	2016	332	Nairobi, Mombasa, Kisumu Eldoret	50.6	Prospective	Cross sectional	Non-random	Hospital	Jaundiced	CLEIA
High risk populations (total 5 studies representing 2221 individuals)										
Day SL (7)	2013	159	Mombasa	7	Prospective	Cohort	Non-random	HIV clinic	Female sex workers	CLEIA
Webale MK (31)	2015	752	Mombasa	5.2	Retrospective	Cross sectional	Non-random	Community	Drug users	5 panel rapid test
Wahome E (32)	2016	525	Coastal Kenya	8	Retrospective	Cohort	Non-random	Community	HIV neg MSM	ELISA
Oyaro M (33)	2018	673	Nairobi, Mombasa, Kisumu	4.3	Prospective	Cross sectional	Non-random	Community	Drug users	ELISA
Jepkemei (27)	2020	112	Nairobi	9.8	Retrospective	Cohort	Non-random	Health clinic	MSM	CLEIA
Moderate risk populations (total 7 studies representing 1861 individuals)										
Harania RS (34)	2008	357	Nairobi	6.2	Prospective	Cross sectional	Non-random	HIV clinic	Adults HIV	ELISA
Kim HN (35)	2011	389	Nairobi	6.9	Retrospective	RCT	Random	HIV clinic	Adults HIV	ELISA
Muriuki BM (36)	2013	290	Nairobi	6.2	Prospective	Cross sectional	Non-random	HIV clinic	Adults HIV	ELISA
EN Njuguna (37)	2015	322	Nairobi, Thika	1	Prospective	Cross sectional	Random	HIV clinic	HIV discordant couples	ELISA
Maina DN (38)	2017	190	Kajiado	5.8	Prospective	Cross sectional	Non-random	HIV clinic	Adults HIV	CLEIA
Greer AE (39)	2017	105	Kisumu	11	Prospective	RCT	Non-random	HIV clinic	HIV discordant couples	CLEIA
Salyani A (26)	2021	208	Nairobi, Kijabe, Mbagathi	5.8	Prospective	Cross sectional	Non-random	HIV clinic	Adults HIV	CLEIA
Low risk populations (total 8 studies representing 6828 individuals)										
Ngaira JA (40)	2016	287	Mbagathi	3.8	Prospective	Cross sectional	Random	Antenatal clinic	Pregnant Women	ELISA
Ly KN (41)	2016	1091	Countrywide	2.1	Retrospective	2 stage cluster	Random	National survey	Urban and rural clusters	ELISA
Wamamba D (42)	2017	2046	Kisumu	3.1	Retrospective	Cross sectional	Non-random	Blood donor clinic	Blood Donors	ELISA
Onyango CG (43)	2018	1215	Kisumu, Siaya, Homa Bay	3.5	Prospective	Cross sectional	Random	Blood donor clinic	Blood Donors	ELISA
Bartonjo G (5)	2019	594	Nakuru, Tenwek	5.6	Prospective	Cross sectional	Random	Blood donor registry	Blood Donors	ELISA
Kisangau EN (44)	2019	295	Makueni	4.5	Prospective	Cross sectional	Random	Hospital rota	Healthcare workers	ELISA
Awili HO (45)	2020	1000	Kisumu, Siaya, Homa Bay	3.4	Prospective	Cross sectional	Non-random	Blood donor clinic	Blood Donors	ELISA
Aluora PO (25)	2020	300	Nairobi	2.3	Prospective	Cross sectional	Random	Blood donor clinic	Blood Donors	CLEIA
Studies of Known HBsAg positive people included for genetic data analysis (total 2 studies representing 90 individuals)										
Kwange SO (46)	2013	32	Nairobi	100	Retrospective	Cross sectional		Blood donor registry	Blood Donors	ELISA
Ochwoto (47)	2013	58	Nairobi	100	Prospective	Cross sectional		Blood donor registry	Blood Donors	ELISA
Studies Looking at Occult HBV Prevalence in HBsAg negative individuals (total 3 studies representing 666 individuals)										
Jepkemei (27)	2020	166	Nairobi	18.7	Retrospective on HBsAg -ve only	Cohort	Non-random	Health clinic	MSM/Jaundice	HBV DNA PCR
Salyani A (26)	2021	196	Nairobi, Kijabe, Mbagathi	5.3	Retrospective on HBsAg -ve only	Cross sectional	Non-random	HIV clinic	Adults HIV	HBV DNA PCR
Aluora PO (25)	2020	293	Nairobi	2.4	Retrospective on HBsAg -ve only	Cross sectional	Random	Blood donor clinic	Blood Donors	HBV DNA PCR

This includes two studies on solely HBsAg +ve patients used only for analysis of genetic data (46,47), and three studies looking at OBI prevalence (25–27). Studies are ranked as very high / high / moderate / low risk groups (presented in order) and within these categories ordered by date of publication.

N – number in the study; RCT – randomised controlled trial; RPHA – Reverse passive haemagglutination; CLEIA – Chemiluminescent immunoassay; ELISA – enzyme linked immunosorbent assay; PCR – polymerase chain reaction; HBsAg – Hepatitis B surface antigen; MSM – men who have sex with men.

We identified eight studies reporting HBsAg prevalence in low-risk populations (total number of participants = 6828), seven studies in people living with HIV (medium risk, total number of participants = 1861), five studies in high-risk groups (total number of participants = 2221) and three studies in the very high-risk group (total number of participants = 492).

Two studies included only HBsAg positive participants (total sample size 90) and studied HBV genotype (46,47). These were not included in our evaluation of HBV prevalence but contributed to our appraisal of HBV sequencing data.

(ii) Geographical distribution of HBV seroprevalence data

Of the 23 studies included, 14 (61%) were in Nairobi or Mombasa, Kenya's most populous cities (Table 3), and all studies were done in the South of the country along the infrastructure routes between Mombasa, Nairobi and Kisumu. These are also the most densely populated Kenyan counties (48). Kisumu was the city most represented in the studies by overall sample size (Figure 2).

Figure 2: Map of Kenya indicating the locations and size of populations from which seroprevalence of HBV infection is reported. Data from a systematic review of papers reporting prevalence and genetic data for HBV in Kenya between 2000 and 2021. The size of the red circle indicates numbers screened in each location, studies in the same location are grouped together. n = number of individuals reported.

247 The mean cohort sample size was 599 participants (IQR 434). 14 studies recruited
248 participants for cohort inclusion at outpatient clinics (8 in HIV clinics, 4 in blood donor
249 clinics, 1 in a health clinic and 1 in antenatal clinic), one recruited participants through the
250 blood donor registry; three through community outreach screening, three recruited hospital
251 inpatients; one recruited healthcare workers and one was a national survey using urban and
252 rural population groups (table 3).
253

254 (iii) Quality assessment of the literature

255 Overall the quality of studies investigating HBV prevalence in Kenya was low (Figure 3 and
256 S2 Fig). 17/23 studies were cross sectional, reporting HBV population prevalence at a single
257 time point only. Most cohort sampling methods were non-randomised and only 4/21
258 studies detailed their sample size calculation (25,26,40,44). Several studies sampled people
259 only from small geographical locations or from a subset of the general population e.g. HIV
260 negative individuals. 21/23 studies used either an enzyme linked immunosorbent assay or
261 chemiluminescent enzyme immunoassay (ELISA or CLEIA) for HBsAg diagnosis. Two studies
262 used reverse passive haemagglutination for diagnosis of CHB, a method previously
263 demonstrated to have poor sensitivity (28,29,49) (Table 3). 2/23 studies went on to screen
264 the HBsAg negative population for HBV DNA via PCR (25,26) and one study included a
265 known HBsAg negative population which they screened for HBV DNA (27).
266

267 **Figure 3: Bar chart showing characteristics of studies identified for a systematic review reporting**
268 **prevalence and genetic data for HBV in Kenya.** This is stratified by number of participants, study
269 design, sampling method, data collection and diagnostic methods. RCT: Randomised controlled trial;
270 EIA: Chemiluminescent enzyme immunoassay; ELISA: Enzyme linked immunosorbent assay.
271

(iv) Biomarkers measured and assessment of treatment criteria

Of the 23 studies examined, 12 reported solely HBsAg detection as a binary result (positive or negative) (table 4). Seven studies combined HBsAg testing with anti-HBc and/or anti-HBs to quantify HBV exposure and/or vaccination rates (7,26,27,31,32,39,41). The mean prevalence of anti-HBc alone or in combination with anti-HBs in those who were HBsAg negative was 38% indicating recovered infection. 4/7 studies reported prevalence of anti-HBs alone in those who were HBsAg negative, indicating likely vaccination, with a mean prevalence of 7.4% (26,31,32,39). Six studies reported HBeAg status and/or HBV DNA quantification (7,33–35,39,50). In those who were HBsAg positive, HBeAg positivity varied between studies from 55% in one study (7) to only 0.7% in another (50).

Table 4: HBV Biomarkers measured by studies reporting prevalence and genetic data for HBV in Kenya

Citation	HBsAg	Anti-HBc or Anti-HBs	HBeAg	ALT	HBV DNA PCR	Fib-4 or APRI	Any imaging (USS/elastography)
Very high-risk population group							
Atina JO (28)	■			■			
Muchiri I (29)	■						
Ochwoto M (30)	■						
High risk population group							
Day SL (7)	■	■	■		■		
Webale MK (31)	■	■	■				
Wahome E (32)	■	■					
Oyaro M (33)	■				■		
Jepkemei (27)	■	■					
Moderate risk population group							
Harania RS (34)	■		■		■		
Kim HN (35)	■		■	■	■		
Muriuki BM (36)	■						
EN Njuguna (37)	■						
Maina DN (38)	■						
Greer AE (39)	■	■	■		■		
Salyani A (26)	■	■					
Low risk population group							
Ngaira JA (40)	■						
Ly KN (41)	■	■					

Wamamba D (42)							
Onyango CG (43)							
Bartonjo G (5)							
Kisangau EN (44)							
Awili HO (45)							
Aluora PO (25)							

A blue square indicates the biomarker was measured in that study. ALT – Alanine aminotransferase; USS – ultrasound, Fib-4 and APRI are non-invasive scores of liver health accredited by the World health Organisation for the assessment of patients with chronic hepatitis B (51) .

Seven studies which measured additional biomarkers alongside HBsAg or anti-HBc/anti-HBs (including HBeAg, HBV DNA and/or liver function tests) were assessed to determine whether participants met local or international HBV treatment guidelines (table 5). Three studies did not present sufficient information to assess treatment eligibility (26–28). Of the remaining four studies representing 167 HBsAg positive participants, 32/167 (19%) people would have possibly met EASL treatment criteria alone if they were aged >30 years, however line-level age data were not presented, so this could not be confirmed. A further 14/167 (8%) participants may have met EASL, South African and Kenyan treatment criteria as they had abnormal ALT alongside HBeAg positivity and high HBV viral load. However, there was insufficient data on the level of ALT derangement to fully determine this. We were unable to assess whether any individuals met criteria for therapy based on NICE guidelines, as these require longitudinal follow up with serial biomarker monitoring.

Table 5: Studies assessed for participants meeting treatment criteria of the NICE, EASL, South African (SA) or Kenyan HBV treatment guidelines as part of a systematic review reporting prevalence and genetic data for HBV in Kenya.

Population Risk Group	Citation	Consideration of meeting national and international treatment criteria
Moderate risk for HBV infection - HIV coinfection	Kim HN (35)	27 HBsAg +ve participants 3/27 would meet EASL treatment criteria if >30 years
Moderate risk for HBV	Greer AE (39)	106 HBsAg +ve.

infection - HIV coinfection		23/106 would meet EASL treatment criteria if >30 years
Moderate risk for HBV infection – HIV coinfection	Harania RS (34)	23 HBsAg +ve participants 11 could have met treatment criteria based on EASL, South African and Kenyan guidelines depending on level of ALT derangement.
High risk for HBV infection – Female sex workers	Day SL (7)	11 HBsAg +ve participants 6/11 Would have met EASL treatment criteria if aged >30 years 3/11 meet EASL, South African and Kenyan guidelines (although Kenyan guidelines recommend successive measurements).
High risk for HBV infection – Drug users	Oyaro M (33)	Measured HBV DNA but results not presented. No HBeAg data. Unable to assess whether meet treatment criteria.
High risk for HBV infection – Drug users	Webale MK (50)	30 HBsAg +ve participants. 1 was HBeAg +ve but nil on HBV DNA or liver disease Unable to assess whether meet treatment criteria.
Very high risk for HBV infection – those presenting to hospital with hepatitis	Atina JO (28)	No information on HBeAg status. ALT not distinguished between patients infected with different hepatitis viruses. Unable to assess whether meet treatment criteria.

HBsAg – hepatitis B surface antigen; HBeAg – hepatitis B e antigen; EASL – European association for the study of the liver; ALT – Alanine aminotransferase.

(v) HBV prevalence estimates in different risk groups

The pooled estimate for HBV prevalence using a random effects model in the low-risk group was 3.31% (95% CI 2.62-4.01%) compared with 5.58% in the moderate risk group (95% CI 3.46-7.7%), 6.17% (95% CI 4.4-7.94%) in the high-risk group and 31.29% (95% CI 9.5-53.09%) in the very high-risk group, however we note that the confidence interval of this estimate is very wide (Figure 4). Heterogeneity was significant ($I^2 > 50\%$) within each subgroup, and highest in the very high-risk sub-group ($I^2 = 97\%$, $p < 0.01$).

Three studies screened for OBI using HBV DNA PCR. These were in populations known to be HBsAg negative and from different HBV risk groups: blood donors, those living with HIV and

318 those presenting to hospital with jaundice. OBI prevalence estimates in these studies were
319 2.4%, 5.3% and 18.7% respectively (25,52,53).
320
321 **Figure 4: Forest plot showing pooled HBV prevalence for populations in different risk groups by**
322 **fixed and random effects model.** This is part of a systematic review reporting prevalence and
323 genetic data for HBV in Kenya between 2000-2021. In each case, the size of the population included
324 is represented by the size of the square. Point prevalence and 95% Confidence Interval (CI) is
325 indicated for each study. Studies are ordered by HBV prevalence in each risk group.
326

327 (vi) Identification of HBV sequences

328 We identified nine studies in total reporting HBV sequence data (full or partial genome),
329 including seven studies from among our 23 seroprevalence studies (Table 3), and an
330 additional two studies that did not contribute to the prevalence estimates (46,47), providing
331 a total of nine studies representing 247 individuals. One study did not clearly report how
332 many HBV samples were sequenced or what the results were, and this study was
333 subsequently excluded from further analysis (39). All the eight remaining studies used PCR
334 of the HBV basal core promotor, Pol or S genes for amplification, followed by Sanger
335 sequencing to determine genotype. Two studies looked for known drug resistance
336 mutations (46,47). Two studies undertook whole genome HBV sequencing in a total of 22
337 patients (30,46). 228/247 (92%) of participants were infected with HBV genotype A, 15/247
338 (6%) with genotype D infection, whilst the remaining were either mixed genotype
339 populations (2/247) or genotype D/E recombinants (2/247) (table 6). Sub-genotype was
340 determined in 146/247 (59%) participants. This was most commonly sub-genotype A1
341 (134/146, 92%) in keeping with previous regional data (54).

342 **Table 6: Numbers of individuals in which HBV genotype or sub-genotype was reported for study**
343 **populations in Kenya, as part of a systematic review on prevalence and genetic data for HBV in**
344 **Kenya from 2000 – 2021.**

Genotype	*Sub-genotype*	*Number of individuals*
A	Not sub-genotyped	94
(total 228)	A1	134
D	Not sub-genotyped	3
(total 15)	D3	3
	D4 or D6	9
D/E Recombinants		2
Unclear		2

345

346 To provide further background context for HBV sequences in Kenya, we identified 25 full
347 length HBV sequences from GenBank (Figure 5). These were generated from three studies,
348 published in 2013, 2015 and 2016 (30,47,55). They primarily represented individuals
349 presenting to hospital with jaundice, (21/25 sequences) infected with genotypes A1 and D.

350

351 **Figure 5: Maximum likelihood phylogenetic tree of full-length consensus HBV sequences from**
352 **Kenya.** Kenyan sequences are those published in GenBank (downloaded 1st Dec 2021) and are
353 shown in red alongside genotype reference sequences in black (1000 bootstrap replicates were
354 performed, and bootstrap support of ≥70% are indicated. Reference sequences from McNaughton et
355 al. (2020) (11).

356

357 5/8 studies provided a detailed analysis of either amino acid or nucleotide substitutions
358 found in the sequenced region of HBV (25,30,35,46,47). 2/5 studies correlated these with
359 known drug resistance mutations to lamivudine and other nucleoside analogues (Table 7)
360 (25,35). One study reported the emergence of drug resistance mutations during lamivudine
361 treatment associated with breakthrough HBV viraemia (35). Multiple other mutations were
362 described in the five studies, some of which were in the major hydrophilic region of the

surface gene, and thus potentially important in influencing both natural and vaccine-mediated immunity (56,57).

Table 7: Details of HBV mutations found in two studies in Kenya which reported presence of drug resistance mutations, as part of a systematic review on prevalence and genetic data for HBV in Kenya from 2000 – 2021.

First Author	*Publication Year and number of participants*	*Mutations Identified*	*Number of individuals with mutation*	*Resistance conferred*
Kim HN (35)	2011 (n=389) 21 participants had HBV sequenced	rt1233V rtA181S rtV207I	3/21 had rt1233V, rtA181S or rtV207I prior to treatment	Adefovir + lamivudine
		A200V M204I	1/21 developed A200V + M204I during lamivudine treatment	Lamivudine
		M204I	1/21 developed M204I during lamivudine treatment	Lamivudine
Patrick Okoti Aluora (25)	2020 (n=300) 9 participants had HBV sequenced (2 HBsAg +ve, 7 HBV DNA +ve only)	rt181T	1/9	Lamivudine, Adefovir
		M129L V163I	9/9	Lamivudine

In Kim HN, two patients developed HBV breakthrough viraemia during lamivudine treatment and developed either RT M204I mutation alone or both A200V and M204I mutations during treatment.

Discussion

Enhanced efforts to characterise the epidemiology and disease burden of HBV are urgently required in Africa, as HBV is present at medium-high endemicity in many populations but has been neglected as a public health problem. Here we have reviewed the literature available on prevalence, genotypes and available sequence data for CHB in Kenya. The pooled prevalence estimates we generated in the different risk groups ranged from 3.31% in the low risk group to 31.29% in the very high-risk group, although wide confidence intervals

379 along with significant heterogeneity (I^2 = 97%) are notable in the very high risk group. This is
380 the group presenting to hospital with jaundice or hepatitis who are likely to have very
381 different pre-test probabilities for HBV infection.
382
383 Most studies included in this review focussed on specific groups of people such as blood
384 donors and those co-infected with HIV. Blood donation in Kenya is voluntary and often done
385 by family members of those in need. There is no financial compensation for donation (58).
386 Routine screening for HBV through the Kenyan National Blood Transfusion Service (KNBTS)
387 consists of ELISA for HBsAg only and there is no nucleic acid amplification testing (NAAT);
388 some OBI may therefore go unidentified. Only one study in this review focussed on
389 pregnant women (40) and one study enrolled healthcare workers (44). These are accessible
390 and important groups to screen for HBV infection given they are engaged with healthcare,
391 likely to come for follow up visits, and interventions can have a significant impact on
392 reducing transmission events. Treatment for pregnant mothers and healthcare workers
393 would reduce onward transmission, and vaccination of babies and uninfected healthcare
394 workers would decrease the overall burden of infection, reducing morbidity and mortality.
395 One study was nationwide (41), but only included those who were HIV negative. More
396 general population screening is lacking, and testing is not routinely done when presenting to
397 healthcare facilities (59). Some areas of the country have been more rigorous in their
398 diagnostic approaches, but this is sporadic and may be increased only when there is a
399 known outbreak of HBV in the local community, as has been the case in other African
400 countries (60,61). This may give a skewed view on population prevalence, but also leads to
401 missed opportunities for diagnosis and intervention, particularly given the very high

402 proportion of those presenting to hospital with jaundice or hepatitis found to be infected
403 with HBV (pooled HBV prevalence 31.29% and 18.7% OBI prevalence).
404
405 It is notable that no studies were done in Northern Kenya, particularly along the borders
406 with Somalia and South Sudan where the prevalence of HBV is substantially higher (for
407 these two neighbouring countries, HBsAg prevalence estimated at 19% and 12%
408 respectively (62,63)), however population density here is also very low (48).
409
410 Along with minimal population screening, there is very little sequencing of HBV in Kenya. Of
411 the 25 papers we reviewed regarding HBV sequencing, only two reported whole genome
412 sequencing, and none did next generation sequencing. We identified only 25 complete HBV
413 genomes from Kenya in a GenBank search. Most available data is from single gene PCR and
414 Sanger sequencing of S and P genes to determine genotype. Expanding these data will allow
415 identification of recombinant genotypes, of which there is evidence in Kenya (64,65), but
416 currently without good understanding of how these translate into clinical outcomes. Deep
417 sequencing data will enable detection of minority variant mutations that may be relevant in
418 emergence of vaccine escape and drug resistance, and also allow description of viral
419 quasispecies, how this correlates with clinical phenotype and other biomarkers.
420
421 Three studies reviewed here screened for OBI using PCR. OBI prevalence was similar to
422 estimated pooled HBsAg prevalence in the associated risk group (2.4%, 5.3% and 18.7% OBI
423 prevalence in low, medium and high/very-risk groups compared with 3.31%, 5.58% and
424 6.17/31.29% pooled HBsAg positivity estimates in the equivalent groups). This indicates that
425 many HBV cases are being missed due to the lack of appropriate screening tests, however

426 the cost and poor availability of HBV DNA testing means it is not currently feasible to use as
427 a universal screening test in Kenya. 20/23 studies solely reported HBsAg positivity diagnosed
428 using other less sensitive tests. It is worth noting that of those presenting to hospital with
429 jaundice who were HBsAg negative, nearly 20% were HBV DNA positive. It is not known
430 whether the jaundice was due to acute HBV infection, or reactivation of chronic disease, but
431 it seems to be an important indicator of HBV infection and screening of all those presenting
432 to hospital with jaundice or hepatitis for OBI with HBV DNA PCR would be optimal. Few
433 studies had characterised HBV exposure and vaccination status using anti-HBc and anti-HBs
434 respectively. This highlights a broader issue around funding and access to laboratory tests
435 needed for complete epidemiological assessment of populations.
436
437 Comparing data available within these studies to a range of African and European treatment
438 algorithms highlights the complexity of guidelines. Most of the studies we included had not
439 been set up to include assessment of treatment criteria, which was likely not feasible within
440 the setting of the study. However, measurement of parameters such as HBeAg, HBV DNA
441 viral load, and liver elastography are clearly outside the reach of existing budgets and
442 infrastructure, and we highlight the need for simpler treatment stratification and cost
443 effectiveness analysis for Kenya and other LMIC settings.
444

445 HIV coinfection as a special case

446 The prevalence of HIV infection in adults in Kenya is 4.2% (95% CI 3.7-4.9%) (66). Seven
447 studies included in this analysis reported HBV prevalence in people living with HIV. The
448 pooled HBV prevalence in this group was 5.58% (95% CI 3.46 – 7.7%). The HIV population is

449 better represented than other groups at risk, as HBV screening is easier to offer to
450 individuals already accessing healthcare for HIV monitoring and treatment. Through this
451 established infrastructure for HIV (including clinics with staff, laboratory support, blood
452 monitoring and drug distribution services), clinical care pathways for HBV could be
453 incorporated. Although tenofovir is available free of charge in Kenya, and is on the WHO list
454 of essential medicines (67), it is only consistently available in combination with lamivudine
455 or emtricitabine for HIV treatment, leaving the HBV monoinfected population unable to
456 access licensed monotherapy.

457

458 Limitations

459 The HBV prevalence estimates we have generated here are wide and vary significantly
460 between the risk groups (pooled risk group prevalence 3.31% - 31.29%). The very high-risk
461 group also has a very wide confidence interval for prevalence estimates. Other sources have
462 different estimates of Kenyan HBV prevalence (e.g. 1% by the CDA Foundation (4)). The CDA
463 data are from 2016, so may be out of date, but the varying estimates reflect difficulties with
464 methods of data collection, varying data sources and data missingness. The overall quality
465 of studies was low, with non-random sample selection common, no calculation of sample
466 size in most studies and nearly all studies being cross sectional representing only a snapshot
467 of HBV prevalence. Only selected populations are represented by the studies we identified,
468 and even those studies seeming to represent the population more broadly are skewed. For
469 example, the study of healthcare workers was primarily female nurses (44) and the
470 nationwide survey only included HIV negative participants (41). OBI was investigated in only
471 three studies. There are no data for the northern part of Kenya, including the region around

472 the border with South Sudan where there might be migration of high prevalence
473 populations. It is likely that prevalence of HBV infection varies significantly by age, region of
474 the country, and according to particular at-risk groups – thus targeted surveillance is
475 important to provide an evidence-base for local and population-specific interventions.
476
477 No children were included in this review. In 2019 Kenya achieved an average coverage of
478 91% of 3rd dose HBV childhood vaccination (68), but in future studies, screening children for
479 HBsAg, anti-HBc, anti-HBs by birth cohort would be important to determine the impact of
480 the vaccine campaign on infection, exposure and immunity, and to identify any populations
481 being missed by vaccine coverage. More evidence is needed to determine whether birth
482 dose HBV immunisation should be routinely deployed.
483
484 We highlight the poor representation of HBV in Kenya with sequencing data, identifying only
485 two studies that undertook whole genome sequencing. 24/25 sequences available on
486 GenBank were from two studies. This is clearly not representative of HBV in the general
487 population, and work is required to determine circulating genotypes and to characterise
488 polymorphisms that are relevant to outcomes of infection, treatment and vaccination.
489

490 # Conclusions

491 We have assimilated epidemiological data for HBV in Kenya, together with clinical and
492 genetic parameters where available, to provide the most refined picture possible to date. A
493 sparse literature highlights the pressing need for clinical and research enterprise, to provide
494 an evidence base for realistic and practical strategies that support country-specific scale-up

495 of screening and treatment. Alongside continued efforts for three-dose vaccine coverage in
496 infancy, these interventions can reduce the burden of disease in those currently infected,
497 and reduce the incidence of new infections, moving Kenya towards 2030 elimination
498 targets.
499

500 **Registration and Protocol**

501 This was not registered as a systematic review. A review protocol was prepared in advance
502 but not published.
503

504 **Funding**

505 LD is funded by a Wellcome Clinician PhD fellowship. CC is funded by GlaxoSmithKline (GSK)
506 and the University of Oxford Nuffield Department of Medicine. PCM is funded by a
507 Wellcome intermediate fellowship (ref 110110Z), UCL/UCLH BRC and the Francis Crick
508 Institute.
509

510 **Acknowledgements**

511 This manuscript was written with the permission of the Director, KEMRI-CGMRC
512

513 **Conflicts**

514 CC (supervised by PCM) receives a contribution of her PhD fellowship funding from GSK.
515
516

517 # References

518 1. World Health Organisation. Global hepatitis report, 2017. 2017.

519 2. O'Hara GA, McNaughton AL, Maponga T, Jooste P, Ocama P, Chilengi R, et al.
520 Hepatitis B virus infection as a neglected tropical disease. PLoS Neglected Tropical
521 Diseases. 2017 Oct 5;11(10).

522 3. WHO. Global health sector strategy on viral hepatitis 2016-2021. Global Hepatitis
523 Programme Department of HIV/AIDS [Internet]. 2016 [cited 2021 Nov 9];(June):56.
524 Available from: https://www.who.int/publications/i/item/WHO-HIV-2016.06

525 4. Countries Dashboard – CDA Foundation [Internet]. [cited 2022 Feb 7]. Available from:
526 https://cdafound.org/polaris-countries-dashboard/

527 5. Bartonjo G, Oundo J, Ng'ang'a Z. Prevalence and associated risk factors of transfusion
528 transmissible infections among blood donors at regional blood transfusion center
529 nakuru and tenwek mission hospital, Kenya. Pan African Medical Journal. 2019;34.

530 6. Otedo AEO. HBV, HIV co-infection at Kisumu District Hospital, Kenya. East African
531 Medical Journal. 2004;81(12):626–30.

532 7. Day SL, Odem-Davis K, Mandaliya KN, Jerome KR, Cook L, Masese LN, et al.
533 Prevalence, Clinical and Virologic Outcomes of Hepatitis B Virus Co-Infection in HIV-1
534 Positive Kenyan Women on Antiretroviral Therapy. PLoS ONE. 2013 Mar 18;8(3).

535 8. Kafeero HM, Ndagire D, Ocama P, Kudamba A, Walusansa A, Sendagire H. Prevalence
536 and predictors of hepatitis B virus (HBV) infection in east Africa: evidence from a
537 systematic review and meta-analysis of epidemiological studies published from 2005
538 to 2020. Archives of Public Health. 2021 Dec 1;79(1).

539 9. Ministry of Health. Kenya, National Policy Guidelines on Immunization 2013. 2013. 20
540 p.
541 10. McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, et al.
542 Insights From Deep Sequencing of the HBV Genome—Unique, Tiny, and
543 Misunderstood. Gastroenterology. 2019;156(2):384–99.
544 11. Mcnaughton AL, Revill PA, Littlejohn M, Matthews PC, Ansari MA. Analysis of
545 genomic-length HBV sequences to determine genotype and subgenotype reference
546 sequences. Journal of General Virology. 2020;101:271–83.
547 12. Ito K, Yotsuyanagi H, Yatsuhashi H, Karino Y, Takikawa Y, Saito T, et al. Risk factors for
548 long-term persistence of serum hepatitis B surface antigen following acute hepatitis B
549 virus infection in Japanese adults. Hepatology [Internet]. 2014 Jan 1 [cited 2021 Nov
550 30];59(1):89–97. Available from:
551 https://onlinelibrary.wiley.com/doi/full/10.1002/hep.26635
552 13. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances
553 [Internet]. Vol. 26, Journal of Gastroenterology and Hepatology (Australia). John
554 Wiley & Sons, Ltd; 2011 [cited 2021 Nov 23]. p. 123–30. Available from:
555 https://onlinelibrary.wiley.com/doi/full/10.1111/j.1440-1746.2010.06541.x
556 14. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL
557 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
558 Journal of Hepatology. 2017;67(2):370–98.
559 15. Spearman CWN, Sonderup MW, Botha JF, van der Merwe SW, Song E, Kassianides C,
560 et al. South African guideline for the management of chronic hepatitis B: 2013. South
561 African Medical Journal. 2013;103(5):335–49.

562 16. Government of Kenya, Gastroenterology Society of Kenya. Guidelines for the
563 Treatment of Chronic Hepatitis B and C Viral Infections in Kenya Gastroenterology
564 Society of Kenya Republic of Kenya. 2016.
565 17. National Clinical Guideline Centre Hepatitis B (chronic) Diagnosis and management of
566 chronic hepatitis B in children, young people and adults Clinical guideline Methods,
567 evidence and recommendations [Internet]. 2013 [cited 2019 Apr 9]. Available from:
568 https://www.nice.org.uk/guidance/cg165/evidence/full-guideline-pdf-190175005
569 18. Government of Kenya, Gastroenterology Society of Kenya. Guidelines for the
570 Treatment of Chronic Hepatitis B and C Viral Infections in Kenya Gastroenterology
571 Society of Kenya Republic of Kenya [Internet]. 2016 [cited 2021 Nov 30]. Available
572 from: kenya-national-hepatitis-guidelines-2014.pdf
573 19. Spearman CWN, Sonderup MW, Botha JF, van der Merwe SW, Song E, Kassianides C,
574 et al. South African guideline for the management of chronic hepatitis B: 2013. South
575 African Medical Journal [Internet]. 2013 [cited 2021 Mar 9];103(5):335–49. Available
576 from: http://www.samj.org.za/index.php/samj/article/view/6452/5035
577 20. PRISMA 2020 Checklist Section and Topic Item # Checklist item Location where item is
578 reported TITLE Title 1 Identify the report as a systematic review. [cited 2022 Feb 16];
579 Available from: http://www.prisma-statement.org/
580 21. Munn Z, MClinSc SM, Lisy K, Riitano D, Tufanaru C. Methodological guidance for
581 systematic reviews of observational epidemiological studies reporting prevalence and
582 cumulative incidence data. International Journal of Evidence-Based Healthcare
583 [Internet]. 2015 Sep 1 [cited 2022 Mar 28];13(3):147–53. Available from:
584 https://journals.lww.com/ijebh/Fulltext/2015/09000/Methodological_guidance_for_
585 systematic_reviews_of.6.aspx

586 22. Katoh K, Rozewicki J, Yamada KD. MAFFT online service: multiple sequence
587 alignment, interactive sequence choice and visualization. 2019 [cited 2022 Apr
588 2];20(4):1160–6. Available from:
589 https://academic.oup.com/bib/article/20/4/1160/4106928
590 23. Fr´ F, Fréd´ F, Lemoine F, Correia D, Lefort V, Doppelt-Azeroual O, et al.
591 NGPhylogeny.fr: new generation phylogenetic services for non-specialists. Web
592 Server issue Published online [Internet]. 2019;47. Available from: http://www.atgc-
593 montpellier.fr/presto
594 24. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL
595 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
596 Journal of Hepatology [Internet]. 2017;67(2):370–98. Available from:
597 https://www.easl.eu/medias/cpg/management-of-hepatitis-B-virus-infection/English-
598 report.pdf
599 25. Aluora PO, Muturi MW, Gachara G. Seroprevalence and genotypic characterization of
600 HBV among low risk voluntary blood donors in Nairobi, Kenya. Virology Journal. 2020
601 Dec 1;17(1).
602 26. Salyani A, Shah J, Adam R, Otieno G, Mbugua E, Shah R. Occult hepatitis B virus
603 infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults. PLoS
604 ONE. 2021 Jan 1;16(1 January).
605 27. Jepkemei KB, Ochwoto M, Swidinsky K, Day J, Gebrebrhan H, McKinnon LR, et al.
606 Characterization of occult hepatitis B in highrisk populations in Kenya. PLoS ONE.
607 2020 May 1;15(5).
608 28. Atina JO, Ogutu EO, Hardison WG, Mumo J. Prevalence of hepatitis A, B, C and human
609 immunodeficiency virus seropositivity among patients with acute icteric hepatitis at

610 the Kenyatta National Hospital, Nairobi. East African Medical Journal [Internet]. 2004
611 Aug 20 [cited 2021 Nov 9];81(4):183–7. Available from:
612 https://www.ajol.info/index.php/eamj/article/view/9152
613 29. Muchiri I, Okoth FA, Ngaira J, Tuei S. Seroprevalence of HAV, HBV, HCV, and HEV
614 among acute hepatitis patients at Kenyatta National Hospital in Nairobi, Kenya. East
615 African Medical Journal [Internet]. 2013 Aug 1 [cited 2021 Dec 2];89(6):199–205.
616 Available from: https://www.ajol.info/index.php/eamj/article/view/91508
617 30. Ochwoto M, Kimotho JH, Oyugi J, Okoth F, Kioko H, Mining S, et al. Hepatitis B
618 infection is highly prevalent among patients presenting with jaundice in Kenya. BMC
619 Infectious Diseases. 2016 Mar 1;16(1).
620 31. Kilongosi MW, Budambula V, Lihana R, Musumba FO, Nyamache AK, Budambula
621 NLM, et al. Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and
622 uninfected injection and Non-injection drug users from coastal Kenya. BMC Infectious
623 Diseases [Internet]. 2015 Jul 30 [cited 2022 Feb 17];15(1):1–8. Available from:
624 https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-015-1060-3
625 32. Wahome E, Ngetsa C, Mwambi J, Gelderblom HC, Manyonyi GO, Micheni M, et al.
626 Hepatitis B Virus Incidence and Risk Factors Among Human Immunodeficiency Virus-1
627 Negative Men Who Have Sex With Men in Kenya. Open Forum Infectious Diseases.
628 2017 Jan 1;4(1).
629 33. Oyaro M, Wylie J, Chen CY, Ondondo RO, Kramvis A. Human immunodeficiency virus
630 infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-
631 infections among drug users in three major Kenyan cities. Southern African Journal of
632 HIV Medicine. 2018;19(1).

633 34. Harania RS, Karuru J, Nelson M, Stebbing J. HIV, hepatitis B and hepatitis C coinfection
634 in Kenya. AIDS. 2008 Jun 19;22(10):1221–2.
635 35. Kim HN, Scott J, Cent A, Cook L, Morrow RA, Richardson B, et al. HBV lamivudine
636 resistance among hepatitis B and HIV coinfected patients starting lamivudine,
637 stavudine and nevirapine in Kenya. Journal of Viral Hepatitis. 2011 Oct;18(10).
638 36. Muriuki BM, Gicheru MM, Wachira D, Nyamache AK, Khamadi SA. Prevalence of
639 hepatitis B and C viral co-infections among HIV-1 infected individuals in Nairobi,
640 Kenya. BMC Research Notes [Internet]. 2013 Sep 9 [cited 2022 Feb 8];6(1):1–6.
641 Available from: https://bmcresnotes.biomedcentral.com/articles/10.1186/1756-
642 0500-6-363
643 37. Njuguna EN, Kinuthia PN, Kinoti M, of Public Health S, Kiarie J. Prevalence and risk
644 factors of previous or active Hepatitis B infection among HIV-1 discordant
645 heterosexual couples. East African Medical Journal [Internet]. 2015 Dec 9 [cited 2021
646 Dec 2];92(10):488–94. Available from:
647 https://www.ajol.info/index.php/eamj/article/view/127082
648 38. Maina D, Karen Hospital T, Kimang AN, Mwangi J, Mutai K, Lihana RW. Genotypes of
649 HBV and HCV among HIV-1 co-infected individuals in Ngong Sub-County, Kenya. East
650 African Medical Journal [Internet]. 2017 Mar 30 [cited 2021 Dec 2];93(12):640–5.
651 Available from: https://www.ajol.info/index.php/eamj/article/view/153976
652 39. Greer AE, Ou SS, Wilson E, Piwowar-Manning E, Forman MS, McCauley M, et al.
653 Comparison of hepatitis b virus infection in HIV-infected and HIV-uninfected
654 participants enrolled in a multinational clinical trial: HPTN 052. Journal of Acquired
655 Immune Deficiency Syndromes. 2017;76(4):388–93.

656 40. Malungu Ngaira JA, Kimotho J, Mirigi I, Osman S, Ng'ang'a Z, Lwembe R, et al.
657 Prevalence, awareness and risk factors associated with hepatitis b infection among
658 pregnant women attending the antenatal clinic at mbagathi district hospital in
659 Nairobi, Kenya. Pan African Medical Journal. 2016 Aug 17;24.
660 41. Ly KN, Kim AA, Umuro M, Drobenuic J, Williamson JM, Montgomery JM, et al.
661 Prevalence of hepatitis B Virus infection in Kenya, 2007. American Journal of Tropical
662 Medicine and Hygiene. 2016 Aug 1;95(2):348–53.
663 42. Wamamba D, Onyango D, Oyugi E, Kanyina E, Obonyo M, Githuku J, et al. Transfusion
664 transmissible infections among walk-in blood donors at Kisumu regional blood
665 transfusion centre, Kisumu County, Kenya, 2015. Lab Medicine. 2017 Nov
666 1;48(4):362–6.
667 43. Onyango KO, Nyamache AK, Kasera GO, Mabeya SN, Nonoh JO. Hepatitis B and C
668 virus co-infections and genetic diversity among HIV-1 infected individuals in Siaya
669 County, Kenya. East African Medical Journal [Internet]. 2021 May 21 [cited 2021 Dec
670 2];98(2):3508–18. Available from:
671 https://www.ajol.info/index.php/eamj/article/view/207458
672 44. Kisangau EN, Awour A, Juma B, Odhiambo D, Muasya T, Kiio SN, et al. Prevalence of
673 hepatitis B virus infection and uptake of hepatitis B vaccine among healthcare
674 workers, Makueni County, Kenya 2017. Journal of Public Health (United Kingdom).
675 2019 Dec 1;41(4):765–71.
676 45. Awili HO, Gitao GC, Muchemi GM. Seroprevalence and Risk Factors for Hepatitis B
677 Virus Infection in Adolescent Blood Donors within Selected Counties of Western
678 Kenya. BioMed Research International. 2020;2020.

679 46. Kwange SO, Budambula NLM, Kiptoo MK, Okoth F, Ochwoto M, Oduor M, et al.
680 Hepatitis B virus subgenotype A1, occurrence of subgenotype D4, and S gene
681 mutations among voluntary blood donors in Kenya. Virus Genes [Internet]. 2013 Dec
682 5 [cited 2022 Jan 31];47(3):448–55. Available from:
683 https://link.springer.com/article/10.1007/s11262-013-0976-1
684 47. Ochwoto M, Chauhan R, Gopalakrishnan D, Chen CY, Ng'ang'a Z, Okoth F, et al.
685 Genotyping and molecular characterization of hepatitis B virus in liver disease
686 patients in Kenya. Infection, Genetics and Evolution. 2013 Dec 1;20:103–10.
687 48. 2019 Kenya Population and Housing Census Volume I: Population by County and Sub-
688 County - Kenya National Bureau of Statistics [Internet]. [cited 2022 Mar 15]. Available
689 from: https://www.knbs.or.ke/?wpdmpro=2019-kenya-population-and-housing-
690 census-volume-i-population-by-county-and-sub-county
691 49. Barbara JAJ, Harrison PJ, Howell DR, Cleghorn TE, Dane DS, Briggs M, et al. A sensitive
692 single reverse passive haemagglutination test for detecting both HBsAg and anti-HBs.
693 Journal of Clinical Pathology [Internet]. 1979;32:1180–3. Available from:
694 http://jcp.bmj.com/
695 50. Kilongosi MW, Budambula V, Lihana R, Musumba FO, Nyamache AK, Budambula
696 NLM, et al. Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and
697 uninfected injection and Non-injection drug users from coastal Kenya. BMC Infectious
698 Diseases [Internet]. 2015 Jul 30 [cited 2022 Jan 31];15(1):1–8. Available from:
699 https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-015-1060-3
700 51. GUIDELINES FOR THE PREVENTION, CARE AND TREATMENT OF PERSONS WITH
701 CHRONIC HEPATITIS B INFECTION. 2015;

702 52. Salyani Id A, Shah J, Adam R, Otieno G, Mbugua E, Shah R. Occult hepatitis B virus
703 infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults. 2021;
704 Available from: https://doi.org/10.1371/journal.pone.0244947
705 53. Jepkemeiid KB, Ochwoto M, Swidinsky K, Day J, Gebrebrhan H, Mckinnon LR, et al.
706 Characterization of occult hepatitis B in high-risk populations in Kenya. 2020 [cited
707 2022 Feb 16]; Available from: https://doi.org/10.1371/journal.pone.0233727.t001
708 54. Rajoriya N, Combet C, Zoulim F, Janssen HLAA. How viral genetic variants and
709 genotypes influence disease and treatment outcome of chronic hepatitis B. Time for
710 an individualised approach? 2017 Dec 1;67(6):1281–97.
711 55. Kibaya R, Lihana R, Kiptoo M, Songok E, Ng'ang'a Z, Osman S, et al. Characterization
712 of HBV Among HBV/HIV-1 Co-Infected Injecting Drug Users from Mombasa, Kenya.
713 Current HIV Research. 2015 Jun 19;13(4):292–9.
714 56. Wu C, Zhang X, Tian Z, Song J, Yang D, Roggendorf M, et al. Biological significance of
715 amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation,
716 secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication.
717 J Gen Virol [Internet]. 2010 [cited 2022 Feb 9];91(Pt 2):483–92. Available from:
718 https://pubmed.ncbi.nlm.nih.gov/19812261/
719 57. Tian Y, Xu Y, Zhang Z, Meng Z, Qin L, Lu M, et al. The Amino Acid Residues at Positions
720 120 to 123 Are Crucial for the Antigenicity of Hepatitis B Surface Antigen. JOURNAL
721 OF CLINICAL MICROBIOLOGY [Internet]. 2007;45(9):2971–8. Available from:
722 https://journals.asm.org/journal/jcm
723 58. CDC Global Health - Kenya - Blog: Giving Blood, Giving Life [Internet]. [cited 2022 Feb
724 8]. Available from:
725 https://www.cdc.gov/globalhealth/countries/kenya/blog/giving.htm

726 59. Tunnage J, Yates A, Nwoga C, Sing'oei V, Owuoth J, Polyak CS, et al. Hepatitis and
727 tuberculosis testing are much less common than HIV testing among adults in Kisumu,
728 Kenya: results from a cross-sectional assessment. BMC Public Health [Internet]. 2021
729 Dec 1 [cited 2022 Mar 15];21(1):1–10. Available from:
730 https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-021-11164-2
731 60. Nosocomial Outbreak of Hepatitis B Virus Infection in a Pediatric Hematology and
732 Oncology Unit in South Africa: Epidemiological Investigation and Measures to Prevent
733 Further Transmission. 2015;
734 61. Thompson P, Morgan CE, Ngimbi P, Mwandagalirwa K, Ravelomanana NLR, Tabala M,
735 et al. Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant
736 women and their neonates in the Democratic Republic of the Congo: a feasibility
737 study. The Lancet Global Health. 2021 Nov 1;9(11):e1600–9.
738 62. Abdulkadir Hassan-Kadle M, Sulaiman Osman M, Petrovich Ogurtsov Mohamed
739 Abdulkadir Hassan-Kadle P, Petrovich Ogurtsov P. Epidemiology of viral hepatitis in
740 Somalia: Systematic review and meta-analysis study. Available from:
741 http://dx.doi.org/10.3748/wjg.v24.i34.3927
742 63. Kirbak ALS, Ng'ang'a Z, Omolo J, Idris H, Usman A, Mbabazi WB. Sero-prevalence for
743 Hepatitis B virus among pregnant women attending antenatal clinic in Juba Teaching
744 Hospital, Republic of South Sudan. Pan Afr Med J [Internet]. 2017 Feb 20 [cited 2022
745 Feb 22];26. Available from: https://pubmed.ncbi.nlm.nih.gov/28451049/
746 64. Ochwoto M, Kimotho JH, Oyugi J, Okoth F, Kioko H, Mining S, et al. Hepatitis B
747 infection is highly prevalent among patients presenting with jaundice in Kenya. BMC
748 Infectious Diseases. 2016 Mar 1;16(1).

749 65. Oyaro M, Wylie J, Chen CY, Ondondo RO, Kramvis A. Human immunodeficiency virus
750 infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-
751 infections among drug users in three major Kenyan cities. Southern African Journal of
752 HIV Medicine. 2018;19(1).
753 66. Kenya | UNAIDS [Internet]. [cited 2022 Feb 22]. Available from:
754 https://www.unaids.org/en/regionscountries/countries/kenya
755 67. eEML - Electronic Essential Medicines List [Internet]. [cited 2022 Feb 22]. Available
756 from: https://list.essentialmeds.org/?query=tenofovir%20disoproxil%20fumarate
757 68. Hepatitis B (HepB3) immunization coverage among 1-year-olds (%) [Internet]. [cited
758 2022 Feb 16]. Available from:
759 https://www.who.int/data/gho/data/indicators/indicator-details/GHO/hepatitis-b-
760 (hepb3)-immunization-coverage-among-1-year-olds-(-)
761

762 # Supporting information

763 **S1 Fig: Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) 2020**
764 **statement checklist**

765 **S2 Fig: Joanna Briggs critical appraisal checklist**.
766

Figure 1


Identification
Records identified via online search using search terms to capture studies of HBV seroprevalence in Kenya between 2000 and 2021*
Excluding:
- Published before 2000 (2003 for AJOL)
- Not in English
- No full text available.
(Total: 272: PubMed =74, Embase = 37, AJOL = 9, Scopus = 152).
Screening
Duplicates removed
n = 171 remaining
Records excluded (n=101):
Embase 23, AJOL 5, Scopus 56, PubMed 17
Records screened for title and abstract
Eligibility
Records removed for:
- Not being relevant to Kenya or no mention of hepatitis B or prevalence/genetic diversity (141)
- Including children without clear description of solely adult data (2)
- No clear sampling strategy (2)
- No diagnostic method documented (1)
Included
23 papers included in the final meta-analysis
(Pubmed = 20, Scopus = 2, AJOL = 1)
2 papers included only when discussing viral sequencing data
Created in BioRender.com bio


Number of particpants
>1000
>500-≤1000
>200 - ≤500
100-≤200
<100
Data Collection Method
Retrospective
Prospective
Sampling Method
Non-random
Random
Study Design
Cluster
Cohort
RCT
Cross Sectional
Other
Diagnostic Method
DNA PCR
EIA
ELISA
0
5
10
15
Number of Studies

Figure 2


Author (Year)
Participants
HBV cases
Prevalence
Prevalence
95%-CI
Very high risk for HBV
Ochwoto (2016) 332 167 50.60 [45.22; 55.98]
Atina (2004) 60 18 30.00 [18.40; 41.60]
Muchiri (2013) 100 13 13.00 [6.41; 19.59]
Common effect model 34.94 [31.01; 38.86]
Random effects model 31.29 [9.50; 53.09]
Heterogeneity: I^2 = 97%, τ^2 = 353.3752, p < 0.01
0 10 20 30 40 50
High risk for HBV
Jepkemei (2020) 112 10 9.80 [4.29; 15.31]
Wahome (2016) 525 42 8.00 [5.68; 10.32]
Day (2013) 159 11 7.00 [3.03; 10.97]
Webale (2015) 752 39 5.20 [3.61; 6.79]
Oyaro (2018) 673 28 4.30 [2.77; 5.83]
Common effect model 5.56 [4.61; 6.52]
Random effects model 6.17 [4.40; 7.94]
Heterogeneity: I^2 = 59%, τ^2 = 2.2417, p = 0.04
0 5 10 15 20
Moderate risk for HBV
Greer (2017) 105 11 11.00 [5.02; 16.98]
Kim (2011) 389 26 6.90 [4.38; 9.42]
Harania (2008) 357 22 6.20 [3.70; 8.70]
Muriuki (2013) 290 17 6.20 [3.42; 8.98]
Maina (2017) 190 11 5.80 [2.48; 9.12]
Salyani (2021) 208 12 5.80 [2.62; 8.98]
Njuguna (2015) 322 3 1.00 [-0.09; 2.09]
Common effect model 3.40 [2.59; 4.21]
Random effects model 5.58 [3.46; 7.70]
Heterogeneity: I^2 = 87%, τ^2 = 5.8452, p < 0.01
0 5 10 15 20
Low risk for HBV
Bartonjo (2019) 594 33 5.60 [3.75; 7.45]
Kisangau (2019) 295 13 4.50 [2.13; 6.87]
Ngaira (2016) 287 10 3.80 [1.59; 6.01]
Onyango (2018) 1215 42 3.50 [2.47; 4.53]
Awili (2020) 1000 34 3.40 [2.28; 4.52]
Wamamba (2017) 2046 63 3.10 [2.35; 3.85]
Aluora (2020) 300 6 2.30 [0.60; 4.00]
Ly (2016) 1091 22 2.10 [1.25; 2.95]
Common effect model 3.11 [2.70; 3.52]
Random effects model 3.31 [2.62; 4.01]
Heterogeneity: I^2 = 56%, τ^2 = 0.5239, p = 0.03
0 2 4 6 8 10

Figure 3


Juba
South Sudan
Ethiopia
Baidoa
بيدوة
Arua
Gulu
Somalia
Uganda
Kampala
Eldoret
Kenya
Kisumu
Nakuru
Entebbe
Garissa
Lake Victoria
Nairobi
Mwanza
Malindi
Arusha
Mombasa
Dodoma
Zanzibar
Tanzania
Dar es Salaam
Google
Map data ©2022

Figure 4


KENYA JX154581 1
KENYA JX154580
KENYA JX154579 1
KENYA JX154582 1
A1 1 KP168423
KENYA KP168423 1
KENYA KP168422 1
KENYA KP168427 1
KENYA KP168426 1
KENYA KP168425 1
KENYA KP168424 1
KENYA KP168428 1
KENYA KP168429 1
KENYA KP168430 1
KENYA KP168431 1
KENYA KP168432 1
KENYA KP168433 1
A1 2 FJ692557
KENYA KP168434 1
A6 GQ331046
A2 EU594385
A X02763
A5 FJ692601
A4 KM606737
A3 AM184126
KENYA KP168435 1
I2 FJ023669
I1 AB562463
C4 KF873526
C5 AP011099
C8 AP011107
C6 EU670263
C10 KJ173333
C1 DQ089781
C UA2 GQ377617
C2 2 GQ377617
C2 3 AP011098
C2 1 KC774182
C UA1 KC774298
C11 AB554015
B6 AB287314
B3 AP011085
B4 AB073835
B2 2 GU815637
B2 1 JQ801514
B1 D23679
E GQ161817
D5 GQ205389
D NC 003977
D3 FJ692507
D2 MF925358
D1 2 KC875277
D1 1 AB222711
D7 FJ904435
KENYA KP168418 1
KENYA KP168417 1
KENYA KP168419 1
KENYA JQ927384 2
KENYA KP168416 1
KENYA KP168421 1
KENYA KP168420 1
D4 FJ692533
G AB056513
J AB486012
F4 KJ843175
F3 MH051986
F2 DQ899143
F1 HM585194
H FJ356715

Figure 5